Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01958580 · ClinicalTrials.gov registry record · NA
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
A NA study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01958580 is a NA study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT01958580, a NA study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy with radiation therapy may kill any tumor cells that remain after surgery.
Interventions
- DRUG Docetaxel
- RADIATION External Beam Radiation Therapy
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Gemcitabine Hydrochloride
- RADIATION Internal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-09-17 |
| Est. Completion | 2017-02-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01958580
The ClinicalTrials.gov registry entry for NCT01958580 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01958580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01958580 about?
NCT01958580 is a clinical study titled "Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery". This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer c...
What is the current status of trial NCT01958580?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2013-09-17. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT01958580?
The interventions under investigation include: Docetaxel (DRUG), External Beam Radiation Therapy (RADIATION), Intensity-Modulated Radiation Therapy (RADIATION), Gemcitabine Hydrochloride (DRUG), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01958580?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.